March 13, 2019- Evidence-based restrictions on inpatient testing for thrombophilia have been approved with the input and review of McLaren physician leaders at multiple levels: Reference Lab Task Force, Subsidiary HVC Teams, and the HVC Steering Committee.
WHY: Inherited thrombophilia refers to a genetic condition that predisposes to an increased risk of venous thromboembolism (VTE). This disorder is prevalent in approximately 7% of the population and the relative risk of VTE is 3- to 20-fold greater in patients with inherited thrombophilia compared with the general population. However, the available evidence suggests that testing for inherited thrombophilia is not recommended in most clinical settings.
Compelling reasons to avoid inpatient thrombophilia testing for patients with unprovoked VTE include:
WHAT: Implement a systems-based project to restrict inpatient thrombophilia testing. Project goals are to support appropriate timing and selection of thrombophilia testing and improve lab stewardship.
HOW: Multimodal approach to include three components:
Questions or concerns about this Clinical Practice Change? Click here to contact the McLaren HVC Program.
American Society of Hematology
Don’t test for thrombophilia in adult patients with venous thromboembolism (VTE) occurring in the setting of major transient risk factors (surgery, trauma or prolonged immobility).
American College of Medical Genetics and Genomics
Don’t order MTHFR genetic testing for the risk assessment of hereditary thrombophilia.
Society for Maternal-Fetal Medicine
Don’t do an inherited thrombophilia evaluation for women with histories of pregnancy loss, intrauterine growth restriction (IUGR), preeclampsia and abruption.
American Society for Reproductive Medicine
Don’t routinely order thrombophilia testing on patients undergoing a routine infertility evaluation.